Press Releases

Here is an up-to-date collection of any information given to the press. It’s a big collection, so try not to look at it all in one sitting.

Press Releases

 
Press Releases
Date Title and Summary View
Feb 9, 2016 BOSTON, Feb. 09, 2016 (GLOBE NEWSWIRE) -- ZIOPHARM Oncology, Inc. (Nasdaq:ZIOP), a biopharmaceutical company focused on new cancer immunotherapies, today announced that the first patient has been enrolled in a Phase 1 clinical study of its second generation non-viral CD19-specific chimeric antigen receptor (CAR) modified T-cell therapy in pa...
PDF
Feb 2, 2016 BOSTON, Feb. 02, 2016 (GLOBE NEWSWIRE) -- ZIOPHARM Oncology, Inc. (Nasdaq:ZIOP), today announced that Laurence Cooper, M.D., Ph.D., Chief Executive Officer, will present at the 18th Annual BIO CEO & Investor Conference on Tuesday, February 9th, 2016 at 1:00 p.m. ET. The conference is being held at the Waldo...
PDF
Jan 11, 2016 BOSTON, Jan. 11, 2016 (GLOBE NEWSWIRE) -- ZIOPHARM Oncology, Inc. (Nasdaq:ZIOP), a biopharmaceutical company focused on new cancer immunotherapies, today announced that its Sleeping Beauty non-viral gene transfer technology was featured in a perspectives article in the January 2016 issue of the journal Nature Medici...
PDF
Jan 6, 2016 BOSTON, Jan. 06, 2016 (GLOBE NEWSWIRE) -- ZIOPHARM Oncology, Inc. (Nasdaq:ZIOP), today announced that Laurence J.N. Cooper, M.D., Ph.D., Chief Executive Officer, will present at the 34th Annual J.P. Morgan Healthcare Conference on Wednesday, January 13th, 2016 at 1:30 p.m. PT at The Westin St. Francis in San Francisco, CA. ...
PDF
Dec 11, 2015 BOSTON, Dec. 11, 2015 (GLOBE NEWSWIRE) -- ZIOPHARM Oncology, Inc. (Nasdaq:ZIOP), a biopharmaceutical company focused on new cancer immunotherapies, today announced that it will host a conference call and webcast slide presentation on Wednesday, December 16, 2015 at 4:30 PM ET to provide a corporate update and discuss the Company's 2016 outlook. ...
PDF
Dec 10, 2015 BOSTON, Dec. 10, 2015 (GLOBE NEWSWIRE) -- ZIOPHARM Oncology, Inc. (Nasdaq:ZIOP), a biopharmaceutical company focused on new cancer immunotherapies, today announced the presentation of the study design and a trial update for a Phase 1b/2 study of Ad-RTS-hIL-12 + veledimex following standard chemotherapy for the treatment of patients with locally adv...
PDF
Dec 7, 2015 BOSTON, Dec. 7, 2015 (GLOBE NEWSWIRE) -- ZIOPHARM Oncology, Inc. (Nasdaq:ZIOP), a biopharmaceutical company focused on new cancer immunotherapies, today announced that results from its CD19-specific CAR T-cell therapy programs were presented at the 57th American Soci...
PDF
Nov 19, 2015 BOSTON, Nov. 19, 2015 (GLOBE NEWSWIRE) -- ZIOPHARM Oncology, Inc. (Nasdaq:ZIOP), a biopharmaceutical company focused on new cancer immunotherapies, today announced that the Company is presenting initial results from an ongoing Phase 1 dose-escalation study of Ad-RTS-hIL-12 + orally administered veledimex in recurrent or progressive glioblastoma or ...
PDF
Nov 2, 2015 BOSTON, Nov. 2, 2015 (GLOBE NEWSWIRE) -- ZIOPHARM Oncology, Inc. (Nasdaq:ZIOP) today announced financial results for the third quarter ended September 30, 2015, and provided an update on the company's recent activities. "The third quarter saw an important expansion of our pipeline with the signing of a new Exclusive Channel Collaboration with o...
PDF
Sep 28, 2015 Companies Form New Collaboration to Pursue Cellular Therapy Approaches to Autoimmune DisorderCompanies to Host Conference Call and Webcast Slide Presentation Today at 5:00 PM ET GERMANTOWN, Md. and BOSTON, Sept. 28, 2015 (GLOBE NEWSWIRE) -- Intrexon Corporation (NYSE:XON), a leader in synthetic biology, announced today it has formed a new Exclu...
PDF
Page:
1
... NextLast